Chemoprevention in colorectal cancer - where we stand and what we have learned from twenty year's experience

Boghossian, Shahe; Hawash, Ahmed

doi:10.1016/j.surge.2011.07.003

Cited by 20 publications

(12 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It is rather a kind of adjuvant therapy involving perturbation of a variety of steps in tumor initiation, promotion and progression. Although a small number of published randomized trials have shown that some chemopreventive therapies may indeed be effective against cancer, there is still need to develop guidelines for management of patients with higher risk of cancer or early treatment with adjuvant chemoprevention therapy (Ulrich et al, 2006;Rostom et al, 2007;Harris et al, 2008;Rothwell et al, 2010Rothwell et al, & 2011Gravitz, 2011;Boghossian et al, 2012;Cook et al, 2013;Mansouri et al, 2013;Sahin et al, 2014).…”

Section: Introductionmentioning

confidence: 99%

Synthesis, COX-1/2 inhibition and antioxidant activities of new oxicam analogues designed as potential chemopreventive agents

et al. 2018

View full text Add to dashboard Cite

Oxicams (e.g. piroxicam, meloxicam) are widely used nonsteroidal anti-inflammatory drugs (NSAIDs). A large body of evidence from epidemiological and preclinical studies has shown that NSAIDs have a chemopreventive effect on different types of cancer, especially in colorectal cancer. Moreover, mounting evidence from preclinical and clinical studies suggests that persistent inflammation functions as a driving force in the journey to cancer. What is more, inflammation induces reactive oxygen and nitrogen species, which cause damage to important cellular components (e.g., DNA, proteins and lipids), which can directly or indirectly contribute to malignant cell transformation. In this study, we discuss the synthesis and the resultant newly synthesized oxicam derivatives which are potentially chemopreventive, and at the same time antioxidant. Compound 9c, with the highest therapeutic index in the LoVo cancer cell line, was found to be the most efficient in ROS scavenging activity under conditions of oxidative stress.

show abstract

Section: Introductionmentioning

confidence: 99%

Synthesis, COX-1/2 inhibition and antioxidant activities of new oxicam analogues designed as potential chemopreventive agents

et al. 2018

View full text Add to dashboard Cite

show abstract

“…The incidence of CRC, moreover, shows also rapidly increasing tendency in Korea [ 3 , 4 ]. Although improved oncologic therapeutic progress and advanced treatment regimen have positively influenced CRC prognostic outcomes, the five-year survival rate remains low in advanced or metastatic CRC [ 5 , 6 ]. Anticancer drugs such as irinotecan and 5-fluorouracil (5-FU) have been administered, often with curative therapy, to eliminate circulating cancer cells.…”

Section: Introductionmentioning

confidence: 99%

Synergistic Effects of Simvastatin and Irinotecan against Colon Cancer Cells with or without Irinotecan Resistance

Jang

Hong

Jang

et al. 2016

Gastroenterology Research and Practice

View full text Add to dashboard Cite

Aims. We here investigated whether the combination of simvastatin and irinotecan could induce the synergistic effect on colon cancer cells with or without resistance to irinotecan. Methods. We investigated cell proliferation assay and assessed cell death detection ELISA and caspase-3 activity assay of various concentrations of simvastatin and irinotecan to evaluate the efficacy of drug combination on colon cancer cells with or without irinotecan resistance. Results. The IC50 values of simvastatin alone and irinotecan alone were 115.4 ± 0.14 μM (r = 0.98) and 62.5 ± 0.18 μM (r = 0.98) in HT-29 cells without resistance to irinotecan. The IC50 values of these two drugs were 221.9 ± 0.22 μM (r = 0.98) and 195.9 ± 0.16 μM (r = 0.99), respectively, in HT-29 cell with resistance to irinotecan. The results of combinations of the various concentrations of two drugs showed that combined treatment with irinotecan and simvastatin more efficiently suppressed cell proliferation of HT-29 cells even with resistance to irinotecan as well as without resistance. Furthermore, the combination of simvastatin and irinotecan at 2 : 1 molar ratio showed the best synergistic interaction. Conclusion. Simvastatin could act synergistically with irinotecan to overcome irinotecan resistance of colon cancer.

show abstract

“…In Asia, CRC is the fourth leading cause of mortality by cancer, and its incidence is increasing [ 4 ]. Therefore, it is clear that, despite decades of advances in its prevention and treatment, CRC remains a substantial cause of death [ 5 ]. The 5-year survival rate is approximately 85% after surgical resection performed in the early stages of CRC; however, the rate is significantly decreased (<50%) in stage III CRC with lymph node metastasis [ 6 ].…”

Section: Introductionmentioning

confidence: 99%

Clinicopathological and prognostic significance of S100A4 overexpression in colorectal cancer: a meta-analysis

et al. 2013

View full text Add to dashboard Cite

BackgroundAccumulated evidence has indicated a correlation between S100A4 expression and colorectal cancer (CRC) progression. However, its prognostic significance for patients with CRC remains inconclusive. To clarify their relationship, a meta-analysis of the relevant published studies was performed.MethodPubMed, Cochrane Library, and Web of Science databases were electronically searched. All studies evaluating the prognostic value of S100A4 expression in CRC patients regarding survival and a series of clinicopathological parameters were included. The effect of S100A4 expression on the overall survival (OS) and disease-free survival (DFS) were measured by pooled hazard ratios (HRs) and 95% confidence intervals (CIs), while the effect of S100A4 expression on the clinicopathological parameters were measured by the pooled odds ratios (ORs) and their 95% CIs.ResultsEleven studies (2,824 patients in total) were included in the meta-analysis. Overall, S100A4 overexpression was significantly associated with worse OS (HR = 1.90, 95% CI: 1.58–2.29, P <0.001), and worse DFS (HR = 2.16, 95% CI: 1.53–3.05, P <0.001) in patients with CRC. Subgroup analyses showed that S100A4 overexpression was significantly correlated with poor OS in Asian, European, and Australian patients and patients treated with surgery or chemotherapy. Additionally, there were significant associations between S100A4 expression and several clinicopathological parameters (tumour location, lymph node metastasis, nodal status, TNM stage, and tumour depth).ConclusionsThis meta-analysis indicates that S100A4 overexpression seems to correlate with tumour progression and poor prognosis of CRC patients. It may be a useful marker to predict progression and prognosis of CRC.Virtual slidesThe virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/8643820431072915

show abstract

Chemoprevention in colorectal cancer - where we stand and what we have learned from twenty year's experience

Cited by 20 publications

References 60 publications

Synthesis, COX-1/2 inhibition and antioxidant activities of new oxicam analogues designed as potential chemopreventive agents

Synthesis, COX-1/2 inhibition and antioxidant activities of new oxicam analogues designed as potential chemopreventive agents

Synergistic Effects of Simvastatin and Irinotecan against Colon Cancer Cells with or without Irinotecan Resistance

Clinicopathological and prognostic significance of S100A4 overexpression in colorectal cancer: a meta-analysis

Contact Info

Product

Resources

About